Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine.

ABSTRACT: Angiogenesis is one of the hallmarks of cancer. Several studies have shown that vascular endothelium growth factor (VEGF) plays a leading role in angiogenesis progression. Antiangiogenic medication has gained substantial recognition and is commonly administered in many forms of human cancer, leading to a rising interest in cancer therapy. However, this treatment method can lead to a deteriorating outcome of resistance, invasion, distant metastasis, and overall survival relative to its cytotoxicity. Furthermore, there are significant obstacles in tracking the efficacy of antiangiogenic treatments by incorporating positive biomarkers into clinical settings. These shortcomings underline the essential need to identify additional angiogenic inhibitors that target numerous angiogenic factors or

SUBMITTER: Alsaab HO 

PROVIDER: S-EPMC7915670 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature